- Home
- ZKH vs HQL Comparison
ZKH vs HQL Comparison
Compare ZKH & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ZKH | HQL |
|---|---|---|
| Founded | 1998 | 1992 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.8M | 533.1M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZKH | HQL |
|---|---|---|
| Price | $3.00 | $18.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 254.9K | 89.4K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | $9.02 | N/A |
| Revenue Next Year | $10.41 | N/A |
| P/E Ratio | ★ N/A | $22.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.20 | $11.88 |
| 52 Week High | $3.90 | $18.10 |
Technical Indicators
Market Signals| Indicator | ZKH | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 67.73 |
| Support Level | $2.81 | $16.40 |
| Resistance Level | $3.13 | N/A |
| Average True Range (ATR) | 0.14 | 0.31 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 27.27 | 93.24 |
Price Performance
Historical ComparisonAbout ZKH ZKH Group Limited
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.